Atlas Private Wealth Advisors Lowers Stock Position in Medtronic PLC $MDT

Atlas Private Wealth Advisors cut its position in shares of Medtronic PLC (NYSE:MDT) by 47.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,819 shares of the medical technology company’s stock after selling 7,164 shares during the quarter. Atlas Private Wealth Advisors’ holdings in Medtronic were worth $745,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares during the period. PFG Investments LLC boosted its position in Medtronic by 4.4% in the second quarter. PFG Investments LLC now owns 8,575 shares of the medical technology company’s stock worth $747,000 after purchasing an additional 360 shares during the last quarter. SOA Wealth Advisors LLC. grew its stake in Medtronic by 282.8% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 777 shares of the medical technology company’s stock valued at $68,000 after purchasing an additional 574 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC increased its position in shares of Medtronic by 17.8% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 32,372 shares of the medical technology company’s stock valued at $2,822,000 after purchasing an additional 4,886 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on MDT. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Citigroup boosted their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Truist Financial dropped their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Finally, JPMorgan Chase & Co. raised their target price on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Stock Up 1.9%

MDT opened at $102.96 on Friday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a market cap of $131.99 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average of $99.60 and a 200 day moving average of $95.64.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).